WHO ICTRP trial
This clinical trial will study how metformin and orlistat influence gut bacteria…
CTRI/2025/02/080001 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/02/080001 |
|---|---|
| Public title | This clinical trial will study how metformin and orlistat influence gut bacteria in women with Polycystic Ovarian Syndrome (PCOS)and track gut bacteria changes and investigate their effects on PCOS symptoms, including weight, insulin resistance, and hormone levels. |
| Scientific title | Orlistat Versus Metformin induced Gut micro-organisms modification in Polycystic ovarian syndrome patients -A Randomized controlled study - Nil |
| Primary sponsor | Dr Saswati tripathy |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: E282- Polycystic ovarian syndrome |
| Interventions | Intervention1: ORLISTAT: 60 MG TWICE DAILY FOR 3 MONTHS Control Intervention1: METFORMIN: 500 MG ONCE DAILY FOR 3 MONTHS |
| Registration date | Jun 2, 2025 |
| Target size | 90 |
| Secondary IDs | Nil |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: